Mach7 Technologies (ASX:M7T) has achieved record sales orders of $25.8M (TCV1) in the first half of FY23, up 17% on $22.1M in H1 FY22.
Revenue of $16.4M was up 14% on $14.3M in H1 FY22, but lower than the $18.1M previously disclosed due to the $1.7M financing component of the 10-year Akumin contract being reclassified as interest income, which will be earned over the contract term.
Mach7 achieved a record Annual Recurring Revenue (ARR) run rate of $16.4M, up 22% on $13.4M at 31 Dec 2021, and Contracted Annual Recurring Revenue (CARR) of $20M, up 19% on $16.8M at 31 Dec 2021.
EBITDA3 of $3.4M was up 13% on $3.1Min H1 FY22, and Cash on hand was $20.6M.